Clinical Trials Directory

Trials / Unknown

UnknownNCT02940184

GLP-1 Signaling in Truncally Vagotomized Subjects

Vagal Mechanisms Mediating the Effects of Glucagon-Like Peptide 1 (GLP-1) on the Endocrine Pancreas - the Entero-endocrine Axis.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
University of Copenhagen · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Accepted

Summary

Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.

Conditions

Interventions

TypeNameDescription
DRUGTablet Sitagliptin 100mg (evening before and morning of experiments)On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
OTHERIntestinal Fructose administrationOn both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube

Timeline

Start date
2016-06-01
Primary completion
2018-10-01
Completion
2018-10-01
First posted
2016-10-20
Last updated
2018-05-22

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02940184. Inclusion in this directory is not an endorsement.